USADA Chief Science Officer, Larry Bowers, Ph.D., discusses the deterrence and the role of detection and testing in the quest for clean competition in Clinical Chemistry’s Point/Counterpoint
As a member of the Endocrine Society’s Scientific Task Force (SSTF), USADA’s Chief Science Officer, Dr. Larry Bowers, was an author of the scientific statement, “Adverse Health Consequences of Performance-Enhancing Drugs,” published in the Endocrine Society journal, Endocrine Reviews.
Building on the existing tests for growth hormone (GH) abuse in sport, scientists continue to make advancements in successfully detecting doping in sport.
From May 27-31, 2014, the American College of Sports Medicine held its 61st annual meeting in Orlando Florida. USADA’s Science Director, Matthew Fedoruk was on hand to present a tutorial lecture, titled New Frontiers against Doping in Sport: Challenging the Omertà.
Inhalation of volumes of concentrated gases such as carbon monoxide, hydrogen sulfide, and xenon, even with medical supervision, may carry serious health risks.
IGF-1 can enhance the production of lean muscle as well as aid in recovery time, but when used without medical necessity, exogenous IGF-1 can cause serious harm.
We have seen an increase in inquires at USADA about the use of Intravenous (IV) Infusions for this purpose, and would like to assist athletes and medical personnel by clarifying this.
What’s the difference between autologous, homologous (allogenic), and heterologous blood transfusions?
Autologous blood transfusion is the collection and re-infusion of the patient’s own blood or blood components.